Beyond Viral Load: The Side Effect Conversation That HIV Clinics in New York Are Still Refusing to Have
There is a version of the HIV treatment success story that gets told often, and told well. Viral loads become undetectable. CD4 counts climb. Patients live long, full lives. It is a genuinely remarkable medical achievement, and it deserves recognition.
But there is another story — quieter, less celebrated, and rarely invited into the examination room. It is the story of the New Yorker who stopped sleeping through the night after starting a new regimen. The one who gained forty pounds in a year and was told it was probably lifestyle. The one who lost interest in sex entirely and was too embarrassed to mention it to their doctor, because the appointment was already running over time, and the numbers looked fine.
The numbers, for many patients, do look fine. That is precisely the problem.
When "Working" Is Not the Same as "Livable"
Contemporary antiretroviral therapy is, by most clinical measures, extraordinarily effective. Regimens that once required handfuls of pills taken multiple times daily have been compressed into single-tablet combinations. Long-acting injectable options have made daily dosing optional for some patients. Resistance barriers are higher. Toxicity profiles, in aggregate, have improved considerably since the early treatment era.
And yet. Side effects persist — not as rare exceptions, but as routine features of life for a substantial portion of people on treatment. Research published in peer-reviewed journals consistently documents that a significant proportion of people living with HIV report treatment-related symptoms that affect their daily functioning. These include insomnia and vivid, disruptive dreams; nausea and gastrointestinal distress; peripheral neuropathy; lipodystrophy, which involves abnormal fat redistribution in the body; dyslipidemia and elevated cardiovascular risk; kidney strain; bone density loss; and sexual dysfunction spanning decreased libido, erectile difficulties, and anorgasmia.
For New Yorkers already navigating the pressures of an expensive, fast-moving city — managing work schedules, housing instability, caregiving responsibilities, mental health — these are not minor inconveniences. They are daily negotiations between what the body needs medically and what the person can actually sustain.
The Silence in the Exam Room
Despite how common these experiences are, many patients report that their providers simply do not ask about them in any meaningful way. Appointments at overburdened clinics in the Bronx, Brooklyn, and Upper Manhattan are often structured around lab results. Viral suppression is confirmed. The next prescription is issued. The patient leaves.
"My doctor would look at my chart and say everything looks great," one Harlem resident living with HIV described in a community forum hosted by a local advocacy organization. "But I hadn't slept more than four hours in a row in eight months. I was having panic attacks I'd never had before. I didn't know how to bring it up, and honestly, I wasn't sure it was related."
This uncertainty — whether a symptom is attributable to medication, to the virus itself, to aging, or to something else entirely — is one of the most significant barriers to honest patient-provider dialogue. Providers, many of whom carry large caseloads, may not have the time or the structured intake processes to routinely screen for quality-of-life concerns. Patients, particularly those from communities that have historically experienced medical dismissal, may not feel empowered to raise issues that seem subjective or that they fear will not be taken seriously.
The result is a clinical environment in which suppression is treated as synonymous with wellness — a conflation that serves the metrics but not always the person.
Metabolic Complications and the Long Game
Among the most consequential and underacknowledged side effect categories are those with long-term health implications. Certain antiretroviral agents — particularly older tenofovir formulations and some integrase inhibitors — have been associated with weight gain that can be significant and difficult to reverse. For patients already at elevated risk of cardiovascular disease or diabetes, this is not a cosmetic concern. It is a compounding health liability.
Kidney function is another area of legitimate concern. Some regimens exert nephrotoxic pressure over time, requiring careful monitoring and, in some cases, regimen modification. Bone density loss, linked to certain antiretroviral drugs as well as to HIV itself, places long-term survivors at elevated fracture risk — a reality that intersects painfully with the city's broader failure to plan adequately for aging New Yorkers with HIV, a crisis this publication has documented in depth.
Cardiovascular risk, meanwhile, remains one of the most pressing long-term concerns for people living with HIV regardless of treatment status — a function of both chronic immune activation and the metabolic effects of some antiretroviral agents. Cardiologists and HIV specialists do not always communicate seamlessly, and patients often find themselves navigating the gap.
Sexual Health, Stigma, and the Symptom Nobody Discusses
Of all the side effect domains, sexual dysfunction may be the most systematically underreported. The reasons are not difficult to identify. Sexuality remains a fraught topic in many clinical environments, particularly for patients who already carry the weight of HIV-related stigma. Raising concerns about libido or sexual performance can feel vulnerable in ways that discussing nausea or fatigue does not.
And yet the data are clear that sexual dysfunction is meaningfully prevalent among people on antiretroviral therapy. It affects quality of life, relationship stability, and — critically — adherence. Patients who experience significant sexual side effects are more likely to modify or discontinue treatment without medical guidance, placing their health at risk.
Providers who create space for these conversations — who ask directly, normalize the topic, and approach it without judgment — are far more likely to help patients find solutions, whether through regimen adjustment, referral to sexual health specialists, or other interventions.
Navigating Alternatives: What Patients Should Know
The good news is that the HIV treatment landscape now offers more options than at any prior point in the epidemic's history. For many patients experiencing intolerable side effects on a given regimen, switching to an alternative is clinically feasible without compromising viral suppression. This is not universally true — resistance profiles, prior treatment history, and comorbidities all factor into what is possible — but it is far more often true than patients may realize.
Long-acting injectable cabotegravir and rilpivirine, administered every one to two months, have offered relief for patients whose side effects were linked to daily oral dosing or specific oral agents. Novel integrase inhibitor combinations have different tolerability profiles than older regimens. The field continues to evolve.
Patients in New York have access to some of the most experienced HIV specialists in the world. They also have access to patient advocates, community health workers, and organizations — including those connected to the broader network of services this publication supports — who can help them prepare for difficult conversations with their providers. Bringing a written list of symptoms, asking explicitly about alternative regimens, and requesting referrals to pharmacists or specialists are all strategies that can shift the dynamic of a clinical encounter.
A Different Measure of Success
Viral suppression matters. It matters enormously, both for individual health and for the prevention of transmission. That is not in dispute.
But suppression is a floor, not a ceiling. The goal of HIV care — stated plainly in the treatment guidelines produced by federal health agencies — is not merely to control the virus. It is to support the long-term health and well-being of the whole person.
For that goal to be realized in New York's clinics, waiting rooms, and community health centers, the conversation has to expand. Side effects are not a secondary concern to be managed privately. They are a central dimension of the lived experience of treatment, and they belong in the exam room, on the intake form, and at the center of the patient-provider relationship.
The numbers may look fine. The question worth asking — and worth answering honestly — is whether the person does too.
